Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1980307,total chromatography time,The total chromatography time for a single sample is approximately 10 min.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),min,10,25141,DB00801,Halazepam
,1980307,sensitivity,A sensitivity of 1 ng/mL for halazepam and nordiazepam is attained when 1 mL of plasma is extracted.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),[ng] / [ml],1,25142,DB00801,Halazepam
,1980307,Ana,Analytical recovery of halazepam and nordiazepam added to the plasma ranged from 89 to 96%.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),%,89 to 96,25143,DB00801,Halazepam
,1980307,oral plasma clearance,Mean oral plasma clearance of halazepam was 24 L/h.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),[l] / [h],24,25144,DB00801,Halazepam
,1980307,apparent elimination half-life,The mean apparent elimination half-life of nordiazepam (45.22 h) is considerably longer than that of halazepam (21.15 h).,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),h,45.22,25145,DB00801,Halazepam
,1980307,apparent elimination half-life,The mean apparent elimination half-life of nordiazepam (45.22 h) is considerably longer than that of halazepam (21.15 h).,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),h,21.15,25146,DB00801,Halazepam
